Taking this further, some investigators have chosen to focus on developing type II inhibitors for specific modes of resistance in cancer models, such as NVP-BVU972 in conjunction with BCR/ABL point mutations in chronic myeloid leukaemia (CML) [76] and NPS-1034 in EGFR inhibitor resistant lung cancer models [77]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.